GlaxoSmithKline announces positive results from Incruse Ellipsa studies

GlaxoSmithKline announced positive results from two studies directly comparing the efficacy and safety of its Incruse Ellipta treatment for chronic obstructive pulmonary disease to two existing treatments.

FTSE 100

8,060.61

15:45 15/11/24

n/a

FTSE 350

4,453.56

15:45 15/11/24

n/a

FTSE All-Share

4,411.85

15:45 15/11/24

n/a

GSK

1,299.00p

15:45 15/11/24

-4.03%

-54.50p

Pharmaceuticals & Biotechnology

19,259.77

15:45 15/11/24

-2.70%

-535.19

The pharmaceuticals giant said that results from a randomised, blinded study showed a once daily dose of the drug achieved a statistically-significant improvement in lung function compared to a once-daily dose of tiotropium.

Meanwhile, results from another, open-label study showed a once-daily dose of Incruse Ellipta was not inferior to a once-daily dose of glycopyrronium.

At 1330 BST, Glaxo shares were up 0.8% at 1,355.60p.